SOUTH SAN FRANCISCO, CA--(Marketwire - Feb 7, 2013) - VistaGen Therapeutics, Inc. ( OTCQB : VSTA ), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announced significant advancements in its stem cell technology licensed from the University Health Network (UHN) in Toronto, Canada. The advancements, which improve VistaGen's ability to develop new stem cell-based bioassay systems and potentially improved cell therapies for human blood system disorders, were reported in the December 2012 edition of Cell Reports, an open-access journal from Cell Press.
The exclusively licensed stem cell technology from UHN, which applies equally to both embryonic stem cells and induced pluripotent stem cells (iPS cells), enables the efficient production of mature hematopoietic (blood) precursor cells.These blood cell precursors give rise to red cells, granulocytes and immune cells (lymphocytes), which represent the majority of the blood cells found in the body.
"In collaboration with our long-term strategic partners at UHN, we continue to pioneer stem cell technology that promises to change the way we develop medicine and apply treatment," stated Shawn K. Singh, CEO of VistaGen. "In addition to creating new capabilities and in vitro assays for drug rescue and predictive toxicology, these advancements open the door to development of new treatments for bone marrow failure, anemia, viral diseases and other conditions that compromise the immune system."
"Due to only partial understanding of the timing and control of the development of definitive hematopoiesis in humans, scientists were previously limited in their ability to identify and produce, from human pluripotent stem cells, the important precursor for mature red and white cells of the blood," said H. Ralph Snodgrass, PhD, VistaGen's President and Chief Scientific Officer. "The identification and characterization of this important precursor provides a readily accessible pluripotent stem cell-derived target cell population that can be expanded and matured into the types of cells needed for novel in vitro assays and our drug rescue efforts, and enables improved technologies and approaches for future cell therapy collaborations."
Dr. Gordon Keller, Chairman of UHN's McEwen Centre for Regenerative Medicine in Toronto and co-founder of VistaGen, stated, "We've been working for many years studying in vitro differentiation of pluripotent stem cells trying to identify, and then expand, the first human cell capable of producing the adult blood and immune system. I believe that we now have a better understanding of this important transition from embryonic to adult hematopoiesis, and have the tools to develop improved methods to expand this cell in large numbers for both drug development and cell therapy applications."
About VistaGen Therapeutics VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism screening. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube, with modern medicinal chemistry to generate novel, safer chemical variants (Drug Rescue Variants) of once-promising small molecule drug candidates. These are drug candidates discontinued by pharmaceutical companies, the U.S. National Institutes of Health (NIH) or university laboratories, after substantial investment in discovery and development, due to heart or liver toxicity or metabolism issues. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans, bringing human biology to the front end of the drug development process.
VistaGen's small molecule prodrug candidate, AV-101, has completed Phase 1 development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects millions of people worldwide.
Visit VistaGen at http://www.VistaGen.com, follow VistaGen at http://www.twitter.com/VistaGen or view VistaGen's Facebook page at http://www.facebook.com/VistaGen.
Cautionary Statement Regarding Forward Looking Statements The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to the success of VistaGen's stem cell technology-based drug rescue, predictive toxicology and metabolism screening activities, further development of stem cell-based bioassay systems, and potentially improved cell therapies, for human blood system disorders or other diseases or conditions, clinical development and commercialization of AV-101 for neuropathic pain or any other disease or condition, its ability to enter into strategic predictive toxicology, metabolism screening, drug rescue and/or drug discovery, development and commercialization collaborations and/or licensing arrangements with respect to one or more drug rescue variants, cell therapies or AV-101, risks and uncertainties relating to the availability of substantial additional capital to support its research, drug rescue, development and commercialization activities, and the success of its research and development plans and strategies, including those plans and strategies related to any drug rescue variant or cell therapy identified and developed by VistaGen, or AV-101. These and other risks and uncertainties are identified and described in more detail in VistaGen's filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC's website at http://www.sec.gov. VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.
See the original post here:
VistaGen's Collaborators Identify Definitive Precursor for Adult Blood and the Immune System
- Mouth Sores from Chemo: Symptoms, Causes, and Treatments - Healthline - February 19th, 2021
- ThermoGenesis Holdings Begins a Year of Celebration of its 35th Anniversary in the Cell Banking and Cell Therapy Industry - PRNewswire - February 19th, 2021
- Meet the women hoping to recruit more stem cells donors from Black communities - CTV News - February 19th, 2021
- CAR T-Cell Therapy Carves Out a Role in Multiple Myeloma - OncLive - February 19th, 2021
- AI project to power the future of stem cell manufacturing - TechCentral.ie - February 17th, 2021
- Promising Results for Stem Cell Treatment of Degenerative ... - February 14th, 2021
- Stem Cell Therapy for Heart Disease - Cleveland Clinic - February 14th, 2021
- Stem Cell Therapy for Stroke Recovery | University of ... - February 14th, 2021
- Stem Cell Treatment: Future of Modern Medicine | Science Times - February 14th, 2021
- Researchers may have found a miracle cure for baldness - BGR - February 14th, 2021
- Types of leukemia: Prevalence, treatment options, and prognosis - Medical News Today - February 14th, 2021
- Jasper Therapeutics Announces Launch of New Clinical Trial with National Heart, Lung, and Blood Institute to Evaluate JSP191 in Sickle Cell Disease -... - February 14th, 2021
- Global Stem Cell Therapy Market Set to Reach USD 214.5 Million by 2024 - The Courier - February 14th, 2021
- Keep it Flowing: Combating COVID-19 Blood Shortages in Cancer Treatment - Curetoday.com - February 14th, 2021
- Network-based screen in iPSC-derived cells reveals therapeutic candidate for heart valve disease - Science - February 14th, 2021
- AlloVir Research Presented at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience - Business Wire - February 14th, 2021
- Orchard Therapeutics talks the benefits of HSC therapy - BioProcess Insider - February 14th, 2021
- Protein Discovery in the Development of New Hearing Hair Cells Could Lead to Treatments for Hearing Loss - SciTechDaily - February 7th, 2021
- Stem cells efficacy confirmed in treating ototoxic hearing loss - Korea Biomedical Review - February 4th, 2021
- Groundbreaking Trial Shows Umbilical-Cord Derived Mesenchymal Stem Cell Infusions Save Lives of Sickest COVID-19 Patients - HospiMedica - January 22nd, 2021
- Massive Growth in Canine Stem Cell Therapy Market Set to Witness Huge Growth by 2027| VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana... - January 22nd, 2021
- Autologous stem cell transplantation versus bortezomib for the first line treatment of systemic light chain amyloidosis in the UK - DocWire News - January 22nd, 2021
- Promising Steps Toward Retinal Cell Transplants to Fight Blindness - HealthDay News - January 22nd, 2021
- Hemostemix Announces the Bread Contract with the Department of Foreign Affairs, Trade & Development Canada - InvestorIntel - January 22nd, 2021
- Trending News on Targeted Oncology, Week of January 22, 2021 - Targeted Oncology - January 22nd, 2021
- Stem Cell Therapy Market Size, Growth Opportunities, Trends, Key Players and Forecast to 2027 - The Courier - January 22nd, 2021
- Time To Book Profit In Fate Therapeutics Stock After A 5x Rally? - Forbes - January 22nd, 2021
- Reid Merryman, MD, on Study Findings Investigating Prognostic Value of ctDNA for Patients with DLBCL - Cancer Network - January 22nd, 2021
- Co-founder Thomas Smeenk on the benefits of Hemostemix autologous stem cell therapy - InvestorIntel - January 12th, 2021
- Covid-19 Impact On Stem Cell Therapy Market 2020 Huge Potential in Future Growth by 2027 | Magellan, Medipost Co., Ltd, Osiris Therapeutics, Inc.,... - January 12th, 2021
- Adipose Derived Stem Cell Therapy Market Analysis and Forecast, 2020-2026 Coherent Market Insights | BioRestorative Therapies, Inc., Celltex... - January 12th, 2021
- New COVID-19 Treatment Uses Stem Cells - Freethink - January 12th, 2021
- Creative Medical Technology Holdings Files Investigational New Drug Application (IND) with FDA for Treatment of Stroke using ImmCelz Regenerative... - January 12th, 2021
- Global Cell Freezing Media for Cell Therapy Market 2020 Dynamics Analysis, Size Witness Growth Acceleration During 2025 - KSU | The Sentinel Newspaper - January 12th, 2021
- Gamida Cell to Present Full Data from Phase 3 Study of Omidubicel at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and... - January 12th, 2021
- Cate Dyer of StemExpress is Named Businesswoman of the Year! - PRNewswire - January 12th, 2021
- Adocia Files Patent on a Hydrogel Scaffold for Cell Therapy in the Treatment of Type 1 Diabetes - Business Wire - January 12th, 2021
- Gene Therapy Market Estimated to Record Highest CAGR by 2024 - KSU | The Sentinel Newspaper - January 12th, 2021
- Stem cell treatment corrects skull shape and restores brain function in mouse model of childhood disorder - National Institutes of Health - January 9th, 2021
- Doctors Make Medical Breakthrough In Treating Severe Cases Of COVID - CBS New York - January 9th, 2021
- Global Stem Cell Therapy Market Report 2020: Market to Recover and Reach $14.76 Billion in 2023 at a CAGR of 19.62% - Forecast to 2030 - Yahoo Finance - January 9th, 2021
- Engineered stem cells that evade immune detection could boost cell therapy and I-O - FierceBiotech - January 9th, 2021
- BENEV Announces Investigative Report on Combination Treatment with Human Adipose Tissue Stem Cell- derived Exosomes and Fractional CO2 Laser for Acne... - January 9th, 2021
- Four promising COVID-19 therapies being tested at nearby UVA - Rappahannock News - January 9th, 2021
- MCL Landscape Adapts to Changes After CAR T-Cell Therapy Approval - OncLive - January 9th, 2021
- Regenerative Medicine Market to Reach Valuation US$ 23.7 Bn by 2027 - GlobeNewswire - January 9th, 2021
- Unlocking The Unlimited Potential Of Stem Cells - CodeBlue - January 9th, 2021
- Stem Cell Treatment Proving Highly Successful In Treating Most Severe Cases Of COVID - Yahoo News - January 9th, 2021
- Factor Bioscience spins out a new cell therapy player with eyes on the clinic within 2 years - Endpoints News - January 9th, 2021
- Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in... - January 9th, 2021
- Top 10 ALS Stories of 2020 - ALS News Today - January 9th, 2021
- Celularity and GX Acquisition Corp. Announce Merger Agreement to Create a Publicly Listed Leader in Allogeneic Cellular Therapy - BioSpace - January 9th, 2021
- Results Show Promising Efficacy in MCL With Next-Generation BTK Inhibitor LOXO-305 - Cancer Network - January 9th, 2021
- BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson's Disease - BioSpace - January 9th, 2021
- Stem Cell Therapy Market Size, Share & Trends Analysis Report By Product Types, And Applications Forecast To 2026 - Farming Sector - January 5th, 2021
- Stem Cell Therapy Market by Treatment,Application,End Users and Geography Forecast To 2027 - LionLowdown - January 5th, 2021
- Stem Cell Therapy Market Analysis, COVID-19 Impact,Outlook, Opportunities, Size, Share Forecast and Supply Demand 2021-2025 - Farming Sector - January 5th, 2021
- AGC Biologics Confirms Cell and Gene Therapy Commercial Expertise as Manufacturer of Orchard Therapeutics' Newly Approved Libmeldy - PRNewswire - January 5th, 2021
- Forge Biologics Announces FDA Clearance of Investigational New Drug Application for Phase 1/2 Clinical Trial (RESKUE) of FBX-101 Gene Therapy for... - January 5th, 2021
- MorphoSys and Incyte Announce the Acceptance of the Swissmedic Marketing Authorization Application f - PharmiWeb.com - January 5th, 2021
- Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in... - January 5th, 2021
- Global Circulating Tumor Cells and Cancer Stem Cells Market To Reach A New Threshold of Growth By 2026 - The Courier - January 5th, 2021
- Catheters Market: Europe and North America Emerge as Leading Regional Market with Well-established Healthcare Infrastructure - BioSpace - January 5th, 2021
- The Worldwide Cell Isolation/Cell Separation Industry is Expected to Grow at a CAGR of 16.8% Between 2020 to 2025 - PRNewswire - January 5th, 2021
- Near-infrared oxidative phosphorylation inhibitor integrates acute myeloid leukemiatargeted imaging and therapy - Science Advances - January 5th, 2021
- Global Cell Therapy Market Report 2020: Market to Recover in 2023 - PRNewswire - January 3rd, 2021
- Lonza's Cocoon will soon make dozens of stem cell therapies all at once - Innovation Origins - January 3rd, 2021
- Induced Pluripotent Stem Cell Derived Human Lung Organoids to Map and Treat the SARS-CoV2 Infections In Vitro - DocWire News - January 3rd, 2021
- Creative Medical Technology Holdings Announces Patent filing based on Preclinical Data in Model of Heart Attack using ImmCelz Regenerative... - January 3rd, 2021
- Haywards Heath carer trying to raise funds for MS treatment - The Argus - January 3rd, 2021
- Chronic graft-versus-host disease in children and adolescents with thalassemia after hematopoietic stem cell transplantation - DocWire News - January 3rd, 2021
- COVID-19-positive cancer patients undergoing active anticancer treatment: An analysis of clinical features and outcomes - DocWire News - January 3rd, 2021
- Cell Therapy Market 2020-2026 by Growth, Demand and Upcoming Business Opportunities - Farming Sector - January 3rd, 2021
- Rheumatoid Arthritis Stem Cell Therapy Market Latest Trends and Future Growth Study by 2029 - Farming Sector - December 31st, 2020
- Creative Medical Technology Holdings Announces Reversion of Liver Failure Using ImmCelz Personalized Cellular Immunotherapy in Preclinical Model -... - December 31st, 2020
- Impacts of COVID 19 on Stem Cell Therapy Market 2020 Size, Demand, Opportunities & Forecast To 2026 - Factory Gate - December 31st, 2020
- Efficacy and safety of mesenchymal stem cells for the treatment of patients infected with COVID-19: a systematic review and meta-analysis protocol -... - December 31st, 2020
- Global Stem Cell Therapy Market Industry 2021 In-depth Market Analysis and Recent Developments, Share, Revenue and Forecast 2025 | Anterogen Co. Inc.... - December 31st, 2020
- Nociceptive neurons shown to boost hematopoiesis | 2020-12-28 - BioWorld Online - December 28th, 2020
- Stem Cell Therapy Market 2020: Demand Analysis, Key Players, Trends, Sales, Supply, Deployment Model, Segments, Organization Size, Production, Revenue... - December 28th, 2020